Table 1 Comparison of general clinical data between the two groups
CMBs group n = 110 | non-CMBs group n = 122 | t orχ2 | P value | |
|---|---|---|---|---|
Patient characteristics | ||||
Male gender (%) | 81 (73.6) | 74 (60.7) | 4.396 | 0.036 |
Age (years) | 68.1 ± 11.4 | 68.0 ± 13.0 | 0.039 | 0.969 |
Smoking (%) | 36 (32.7) | 49 (40.2) | 1.378 | 0.240 |
Hypertension history (%) | 81 (73.6) | 72 (59.0) | 5.506 | 0.019 |
Diabetes history (%) | 48 (43.6) | 37 (30.3) | 4.413 | 0.036 |
AF status | 6.380 | 0.012 | ||
AF history (%) | 56 (50.9) | 82 (67.2) | ||
New diagnosis of AF (%) | 54 (49.1) | 40 (32.8) | ||
AF type | 0.045 | 0.833 | ||
Paroxysmal AF (%) | 40 (36.4) | 46 (37.7) | ||
Persistent AF (%) | 70 (63.6) | 76 (62.3) | ||
CI history (%) | 22 (20.0) | 21 (17.2) | 0.298 | 0.585 |
CH history (%) | 4 (3.6) | 2 (1.6) | 0.916 | 0.339 |
NIHSS score | 6.3 ± 5.2 | 7.1 ± 5.6 | −0.864 | 0.389 |
CHA2DS2VASc score | 5.0 ± 1.2 | 5.4 ± 1.2 | −2.922 | 0.004 |
HAS-BLED score | 1.6 ± 0.4 | 1.5 ± 0.5 | 0.152 | 0.880 |
Antithrombotic therapy | 11.981 | 0.001 | ||
Anticoagulant therapy | 54 (49.1) | 87 (71.3) | 1.180 | 0.554 |
Warfarin (%) | 14 (12.7) | 30 (24.6) | ||
Dabigatran (%) | 36 (32.7) | 52 (42.6) | ||
Rivaroxaban (%) | 4 (3.6) | 5 (4.1) | ||
Antiplatelet therapy | 56 (50.9) | 35 (28.7) | 0.005 | 0.946 |
Aspirin (%) | 34 (30.9) | 21 (17.2) | ||
Clopidogrel (%) | 22 (20.0) | 14 (11.5) | ||